Stock 6539 DV BIOMED CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials DV Biomed Co., Ltd.

Equities

6539

TW0006539000

Biotechnology & Medical Research

End-of-day quote Taipei Exchange
Other stock markets
 03:30:00 10/05/2024 am IST 		5-day change 1st Jan Change
45.5 TWD -1.09% Intraday chart for DV Biomed Co., Ltd. +1.11% -7.43%
11/04 DV Biomed Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 DV Biomed Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 2,621 3,018 4,193 3,479 3,287 2,914
Enterprise Value (EV) 1 2,000 2,741 3,905 3,102 3,168 3,025
P/E ratio 18.2 x 18.2 x 13.9 x 11.4 x 11.8 x 18 x
Yield 4.67% 3.25% 5.69% 7.52% 9.64% -
Capitalization / Revenue 1.4 x 1.56 x 2.31 x 1.9 x 1.76 x 1.89 x
EV / Revenue 1.07 x 1.42 x 2.16 x 1.7 x 1.69 x 1.97 x
EV / EBITDA 8.18 x 11.1 x 10.8 x 5.98 x 6.37 x 11.5 x
EV / FCF 34.8 x 42.9 x 12.4 x 8.28 x 9.72 x -3,426 x
FCF Yield 2.87% 2.33% 8.07% 12.1% 10.3% -0.03%
Price to Book 2.74 x 2.94 x 3.46 x 2.95 x 2.87 x 2.81 x
Nbr of stocks (in thousands) 61,720 61,720 60,850 60,459 59,758 59,292
Reference price 2 42.47 48.90 68.91 57.54 55.00 49.15
Announcement Date 18/04/19 15/04/20 15/04/21 25/04/22 20/04/23 11/04/24
1TWD in Million2TWD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 1,866 1,930 1,812 1,827 1,871 1,538
EBITDA 1 244.4 247.9 360.4 518.9 497.6 264.1
EBIT 1 184.9 163.1 267.7 418.6 380.7 173.5
Operating Margin 9.91% 8.45% 14.78% 22.91% 20.35% 11.28%
Earnings before Tax (EBT) 1 167.6 149.1 336.6 395.8 357.3 188.4
Net income 1 144.2 166.3 301.4 304.6 281.3 162.9
Net margin 7.73% 8.61% 16.64% 16.67% 15.03% 10.59%
EPS 2 2.334 2.691 4.940 5.028 4.680 2.725
Free Cash Flow 1 57.46 63.91 315.3 374.5 325.8 -0.8831
FCF margin 3.08% 3.31% 17.4% 20.49% 17.41% -0.06%
FCF Conversion (EBITDA) 23.51% 25.78% 87.47% 72.17% 65.46% -
FCF Conversion (Net income) 39.86% 38.44% 104.6% 122.95% 115.83% -
Dividend per Share 2 1.984 1.588 3.921 4.329 5.300 -
Announcement Date 18/04/19 15/04/20 15/04/21 25/04/22 20/04/23 11/04/24
1TWD in Million2TWD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - 111
Net Cash position 1 621 277 288 377 119 -
Leverage (Debt/EBITDA) - - - - - 0.4207 x
Free Cash Flow 1 57.5 63.9 315 374 326 -0.88
ROE (net income / shareholders' equity) 12.4% 8.49% 23.5% 25.6% 24.2% 14%
ROA (Net income/ Total Assets) 8.4% 5.79% 8.79% 14.2% 12.2% 5.61%
Assets 1 1,717 2,870 3,427 2,145 2,307 2,903
Book Value Per Share 2 15.50 16.60 19.90 19.50 19.20 17.50
Cash Flow per Share 2 10.20 9.630 8.830 9.220 7.640 3.800
Capex 1 155 155 93.3 62.2 121 297
Capex / Sales 8.3% 8.03% 5.15% 3.41% 6.45% 19.3%
Announcement Date 18/04/19 15/04/20 15/04/21 25/04/22 20/04/23 11/04/24
1TWD in Million2TWD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
DV BIOMED CO., LTD. Stock DV Biomed Co., Ltd.
-7.43% 83.8M
MODERNA, INC. Stock Moderna, Inc.
+17.96% 44.96B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.17% 42.65B
LONZA GROUP AG Stock Lonza Group AG
+48.77% 41.85B
CELLTRION, INC. Stock Celltrion, Inc.
-4.27% 29.04B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.42% 26.08B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.39% 19.03B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+4.86% 12.75B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.29% 12.06B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.50% 11.75B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. 6539 Stock
  4. Financials DV Biomed Co., Ltd.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW